ZA201103178B - Anti-tgf-beta receptor ii antibodies - Google Patents

Anti-tgf-beta receptor ii antibodies

Info

Publication number
ZA201103178B
ZA201103178B ZA2011/03178A ZA201103178A ZA201103178B ZA 201103178 B ZA201103178 B ZA 201103178B ZA 2011/03178 A ZA2011/03178 A ZA 2011/03178A ZA 201103178 A ZA201103178 A ZA 201103178A ZA 201103178 B ZA201103178 B ZA 201103178B
Authority
ZA
South Africa
Prior art keywords
tgf
antibodies
beta receptor
receptor
beta
Prior art date
Application number
ZA2011/03178A
Other languages
English (en)
Inventor
Yan Wu
Original Assignee
Imclone Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imclone Llc filed Critical Imclone Llc
Publication of ZA201103178B publication Critical patent/ZA201103178B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ZA2011/03178A 2008-11-07 2011-04-29 Anti-tgf-beta receptor ii antibodies ZA201103178B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19869708P 2008-11-07 2008-11-07
US17036909P 2009-04-17 2009-04-17
PCT/US2009/062450 WO2010053814A1 (en) 2008-11-07 2009-10-29 Anti-tgf-beta receptor ii antibodies

Publications (1)

Publication Number Publication Date
ZA201103178B true ZA201103178B (en) 2012-10-31

Family

ID=41508691

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2011/03178A ZA201103178B (en) 2008-11-07 2011-04-29 Anti-tgf-beta receptor ii antibodies

Country Status (19)

Country Link
US (2) US8147834B2 (enExample)
EP (1) EP2356152A1 (enExample)
JP (1) JP5667067B2 (enExample)
KR (1) KR101283856B1 (enExample)
CN (1) CN102209727B (enExample)
AR (1) AR073909A1 (enExample)
AU (1) AU2009311375B2 (enExample)
BR (1) BRPI0921263A2 (enExample)
CA (1) CA2742961C (enExample)
EA (1) EA025169B1 (enExample)
IL (1) IL211842A (enExample)
JO (1) JO3096B1 (enExample)
MX (1) MX2011004871A (enExample)
NZ (1) NZ591943A (enExample)
PA (1) PA8846101A1 (enExample)
SG (1) SG10201401280TA (enExample)
TW (1) TWI384998B (enExample)
WO (1) WO2010053814A1 (enExample)
ZA (1) ZA201103178B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2013007936A (es) * 2011-01-06 2013-08-09 Glaxo Group Ltd Ligandos que se unen al receptor ii del factor de crecimiento transformante-beta.
AR086044A1 (es) 2011-05-12 2013-11-13 Imclone Llc Anticuerpos que se unen especificamente a un dominio extracelular de c-kit y usos de los mismos
KR20170074243A (ko) 2014-10-31 2017-06-29 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 변형된 t 세포의 생성 방법 및 조성물
AU2015380397B2 (en) 2015-01-31 2021-10-21 The Trustees Of The University Of Pennsylvania Compositions and methods for T cell delivery of therapeutic molecules
SI3370768T1 (sl) 2015-11-03 2022-04-29 Janssen Biotech, Inc. Protitelesa, ki se specifično vežejo na PD-1, in njihove uporabe
EP4169942A1 (en) 2016-03-11 2023-04-26 Scholar Rock, Inc. Tgfbeta1-binding immunoglobulins and use thereof
AU2017268469C1 (en) * 2016-05-20 2025-01-02 President And Fellows Of Harvard College Gene therapy methods for age-related diseases and conditions
AR109770A1 (es) * 2016-10-18 2019-01-23 Lilly Co Eli ANTICUERPOS DEL RECEPTOR II DE TGF-b
US20180207267A1 (en) * 2017-01-06 2018-07-26 Scholar Rock, Inc. Isoform-specific, context-permissive tgfb1 inhibitors and use thereof
CN106884005A (zh) * 2017-01-19 2017-06-23 樊克兴 一种结直肠癌抗原特异性t细胞的制备方法
CN111601616A (zh) 2017-10-24 2020-08-28 美真达治疗公司 用于耗尽cd117+细胞的组合物和方法
JP7280254B2 (ja) 2017-10-24 2023-05-23 マジェンタ セラピューティクス インコーポレイテッド Ｃｄ１１７＋細胞を減少させるための組成物及び方法
WO2019084053A1 (en) * 2017-10-24 2019-05-02 Magenta Therapeutics, Inc. COMPOSITIONS AND METHODS FOR DEPLOYING CD117 + CELLS
CN107973853B (zh) * 2017-12-12 2021-04-30 山西农业大学 一种利用特征多肽制备Smad2蛋白特异性抗体的方法及其应用
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
PH12022551527A1 (en) * 2019-12-24 2024-01-29 Merus Nv Tgf-beta-rii binding proteins
KR102314157B1 (ko) * 2020-01-10 2021-10-19 주식회사 뉴클릭스바이오 TGF-β 수용체에 특이적으로 결합하는 항체 및 이의 이용방법
JP2025512025A (ja) * 2022-04-15 2025-04-16 バイオサイトジェン ファーマシューティカルズ （ベイジン） カンパニー リミテッド 抗ｃｄ４０抗体及びその使用
CN116178567B (zh) * 2022-10-28 2025-01-28 四川大学华西医院 一种靶向TGFβRII的嵌合抗原受体及其用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5565332A (en) * 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
JP4124815B2 (ja) * 1991-10-31 2008-07-23 ホワイトヘッド インスティチュート フォー バイオメディカル リサーチ ＴＧＦ−β型受容体ｃＤＮＡおよびその用途
JP2001206899A (ja) * 1999-11-18 2001-07-31 Japan Tobacco Inc ＴＧＦ−βＩＩ型受容体に対するヒトモノクローナル抗体及びその医薬用途
JP2004121001A (ja) * 2002-08-07 2004-04-22 Japan Tobacco Inc ＴＧＦ−βＩＩ型受容体に対する高親和性モノクローナル抗体
US20090186076A1 (en) * 2006-02-01 2009-07-23 Kazunori Kataoka Combined Use of TGF-Beta Signaling Inhibitor and Antitumor Agent

Also Published As

Publication number Publication date
KR101283856B1 (ko) 2013-07-15
MX2011004871A (es) 2011-07-13
JO3096B1 (ar) 2017-03-15
WO2010053814A1 (en) 2010-05-14
CA2742961A1 (en) 2010-05-14
KR20110067155A (ko) 2011-06-21
NZ591943A (en) 2012-11-30
IL211842A (en) 2016-09-29
AU2009311375A1 (en) 2010-05-14
US20100119516A1 (en) 2010-05-13
CN102209727B (zh) 2014-07-30
JP5667067B2 (ja) 2015-02-12
US8147834B2 (en) 2012-04-03
CA2742961C (en) 2016-08-30
EA201170659A1 (ru) 2011-10-31
EA025169B1 (ru) 2016-11-30
TW201026326A (en) 2010-07-16
IL211842A0 (en) 2011-06-30
BRPI0921263A2 (pt) 2015-08-04
TWI384998B (zh) 2013-02-11
AU2009311375B2 (en) 2014-07-31
CN102209727A (zh) 2011-10-05
JP2012508170A (ja) 2012-04-05
SG10201401280TA (en) 2014-05-29
AR073909A1 (es) 2010-12-09
US20120177666A1 (en) 2012-07-12
EP2356152A1 (en) 2011-08-17
PA8846101A1 (es) 2010-06-28

Similar Documents

Publication Publication Date Title
SG10201401280TA (en) Anti-TGF-Beta Receptor II Antibodies
AP3371A (en) Anti-IGF antibodies
EP2241578A4 (en) ANTI-CLDN6 ANTIBODIES
EP2331579A4 (en) MONOCLONAL ANTIBODIES
ZA201102119B (en) Improved antibody libraies
GB0821100D0 (en) Antibodies
GB0708002D0 (en) Antibodies
IL214996A0 (en) Anti-bcma antibodies
GB0920127D0 (en) Antibodies
GB0909906D0 (en) Antibodies
LT2853545T (lt) Antikūnai, specifiniai ige atžvilgiu
SG10201601279SA (en) Monoclonal Antibody STRO-4
EP2427496A4 (en) ANTI-VEGF-D ANTIBODIES
ZA201006099B (en) Anti-tyrp1 antibodies
GB0718737D0 (en) Antibodies
GB0920324D0 (en) Antibodies
ZA201200372B (en) Anti-tgf-beta receptor type ii single domain antibodies
ZA201007976B (en) Anti-pirb antibodies
IL212900A0 (en) Isoform specific anti-her4 antibodies
EP2499256A4 (en) ANTI-C-MPL ANTIBODIES
GB0818356D0 (en) Antibodies
GB0911770D0 (en) Antibody
HK1158217A (en) Anti-tgf-beta receptor ii antibodies
GB0823562D0 (en) Antibodies
GB0806230D0 (en) Antibodies